Ozer Muhammet, Abbasi Fatemah, Mahdi Mohammed, Goksu Suleyman Yasin, Struble Eric
Department of Internal Medicine, Capital Health Regional Medical Center, Trenton, NJ, United States.
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States.
J Cardiol Cases. 2021 Mar 14;24(3):144-147. doi: 10.1016/j.jccase.2021.02.016. eCollection 2021 Sep.
The World Health Organization nominated SARS-CoV-2 as the cause of the Coronavirus Disease 2019 (COVID-19) and has been granted as a pandemic. COVID-19 is an emerging threat due to the risk of microvascular, venous, and arterial thrombosis, thereby exacerbating organ injury and mortality. Although the exact mechanism of extensive thromboembolism and myocardial injury caused by SARS-CoV-2 is not illuminated, it is clear that COVID-19 related hypercoagulation increasing the fatality of the disease. Herein, we reported a patient with extensive biventricular thrombi along with the new-onset severe systolic dysfunction as an unusual catastrophic presentation of COVID-19. In our patient, there was both a right atrial "clot in transit" from his DVT as well as extensive muralized biventricular thrombus from severe global hypokinesis. We believe that the hypercoagulable state of his COVID-19 infection, along with severe systolic dysfunction, caused this unusual presentation. Although the hypercoagulable state of COVID-19 is well recognized, there have not been any reported cases of extensive de-novo intracardiac thrombus as of yet. We urge awareness of severe and potentially fatal extensive thrombosis and cardiac failure as the initial clinical presentation of possible SARS-CoV-2. < Thrombotic manifestations are correlated with the high mortality rate in COVID-19; thus, strategies to prevent thrombosis have critical importance. The hypercoagulable state of COVID-19, along with cardiac injury, can lead to an extensive intracardiac thrombus and severe systolic dysfunction even in young patients who don't have previous cardiovascular comorbidities. We urge awareness of severe and potentially fatal extensive thrombosis and cardiac failure as the initial clinical presentation of COVID-19.>.
世界卫生组织将严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)认定为2019冠状病毒病(COVID-19)的病原体,该病已被列为大流行病。由于微血管、静脉和动脉血栓形成的风险,COVID-19成为一种新出现的威胁,进而加剧器官损伤和死亡率。尽管SARS-CoV-2导致广泛血栓栓塞和心肌损伤的确切机制尚不明晰,但很明显,COVID-19相关的高凝状态增加了该疾病的致死率。在此,我们报告了一名患者,其出现广泛的双心室血栓以及新发的严重收缩功能障碍,这是COVID-19一种不寻常的灾难性表现。在我们的患者中,既有来自深静脉血栓形成的右心房“移动性血栓”,也有因严重全心运动减弱形成的广泛双心室附壁血栓。我们认为,其COVID-19感染导致的高凝状态,连同严重的收缩功能障碍,造成了这种不寻常的表现。尽管COVID-19的高凝状态已得到充分认识,但截至目前尚未有广泛新发心内血栓的报道病例。我们敦促人们认识到严重且可能致命的广泛血栓形成和心力衰竭可能是SARS-CoV-2感染的初始临床表现。<血栓形成表现与COVID-19的高死亡率相关;因此,预防血栓形成的策略至关重要。COVID-19的高凝状态,连同心脏损伤,即使在没有既往心血管合并症的年轻患者中也可导致广泛的心内血栓形成和严重的收缩功能障碍。我们敦促人们认识到严重且可能致命的广泛血栓形成和心力衰竭可能是COVID-19的初始临床表现。>